The Emerging Role of Interleukin 1β (IL-1β) in Cancer Cachexia.

Treatment of cancer cachexia remains an unmet need. The host-tumour interface and the resulting sequestration of the pro-inflammatory cytokine Il-1β is critical in cachexia development. Neuroinflammation mediated via IL-1β through the hypothalamic pituitary axis results in increased muscle proteolysis and adipose lipolysis, thus creating a prolonged stress-like environment with loss of appetite and increased resting energy expenditure. Recent trials using a monoclonal antibody targeting IL-1β, canakinumab, have shown a potential role in lung cancer; however, a potential role of targeting IL-1β to treat cachexia in patients with lung cancer is unclear, yet the underlying pathophysiology provides a sound rationale that this may be a viable therapeutic approach. © 2021. The Author(s).

Citation

Barry J Laird, Donald McMillan, Richard J E Skipworth, Marie T Fallon, D Robert Paval, Iain McNeish, Iain J Gallagher. The Emerging Role of Interleukin 1β (IL-1β) in Cancer Cachexia. Inflammation. 2021 Aug;44(4):1223-1228

Mesh Tags

Substances

PMID: 33907915

search → result